Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological, and pathological disease in a Syrian hamster model of COVID-19

Mostrar otras versiones (1)

There remains an unmet need for globally deployable, low-cost therapeutics for the ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Previously, we reported on the isolation and in vitro characterization of a potent single-domain nanobody, NIH-CoVnb-112, specific for the...

Descripción completa

Detalles Bibliográficos
Autores principales: Esparza, Thomas J., Chen, Yaozong, Martin, Negin P., Bielefeldt-Ohmann, Helle, Bowen, Richard A., Tolbert, William D., Pazgier, Marzena, Brody, David L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928829/
https://www.ncbi.nlm.nih.gov/pubmed/35289719
http://dx.doi.org/10.1080/19420862.2022.2047144

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928829/
https://www.ncbi.nlm.nih.gov/pubmed/35289719
http://dx.doi.org/10.1080/19420862.2022.2047144

Ejemplares similares